Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Goldman Sachs analyst James Quigley maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK875.00. The company’s shares closed yesterday at DKK625.57.

UBS analyst upgraded Novo Nordisk (NVO) to Buy from Neutral with a price target of DKK 750, down from DKK 1,100. Novo Nordisk is “well placed” to continue to benefit from the high demand for ...

With (almost) no fees and unlimited refunds for ATM charges, Novo business checking is a good option for small-business owners on the go. But Novo’s customer support is lacking, and you can’t ...

In a report released today, Kerry Holford from Berenberg Bank maintained a Hold rating on Novo Nordisk (0QIU – Research Report), with a price target of DKK725.00. The company’s shares closed ...

Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for legal issues in China. One of these stocks has a stronger investment ...

Novo Nordisk also boasted a 55.6% share of the GLP-1 drug space, compared to 54.4% as of August 2023. The company's most famous brands, Wegovy and Ozempic, are both GLP-1s.

To hear Novo tell it, the outsourcing group OFA shouldn’t be allowed to place liraglutide on its compounding list given that FDA-approved generics to Victoza are available. Further, the OFA has ...

The biggest talking point in the pharmaceutical industry at the moment revolves around treatments known as glucagon-like peptide-1 (GLP-1) agonists. GLP-1 agonists are used to treat diabetes and ...

Novo Nordisk recently announced results for a new weight loss candidate, CagriSema. Data from the trial underwhelmed investors, and Novo stock is down almost 20% on the news. However, investors ...

Novo Nordisk should deliver a 24% CAGR over two years, driven by robust obesity drug market growth and improved operational performance, with an intrinsic value implying a 29% safety margin.

Novo Nordisk (NVO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in ...